Literature DB >> 31708665

Gemcitabine-induced pseudocellulitis: a case report and review of the literature.

H Bami1, C Goodman1,2, G Boldt2, M Vincent1,2.   

Abstract

Gemcitabine is a chemotherapeutic agent used in a wide variety of solid tumours. Known side effects include a dose-limiting myelosuppressive toxicity, mild rash, and radiation-dependent dermatitis. Rarely, localized inflammation in the form of pseudocellulitis has also been observed. We present the case of a 77-year-old woman with a history of a Whipple procedure for pancreatic adenocarcinoma who presented to the emergency department after the start of gemcitabine therapy with increased erythema, swelling, and tenderness in her lower legs. Relevant past medical history included peripheral vascular disease, dyslipidemia, and hypertension. A diagnosis of gemcitabine-induced pseudocellulitis aggravated by venous stasis was confirmed after an extensive workup. This case report and the literature review describe this rare reaction, highlighting the need for increased recognition to avoid unnecessary therapeutic intervention. 2019 Multimed Inc.

Entities:  

Keywords:  Gemcitabine; pancreatic adenocarcinoma; pseudocellulitis

Year:  2019        PMID: 31708665      PMCID: PMC6821114          DOI: 10.3747/co.26.5007

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  21 in total

1.  Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine.

Authors:  H J Burstein
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Recurrent lower extremity pseudocellulitis.

Authors:  Alex Korniyenko; James Lozada; Aditi Ranade; Gagangeet Sandhu
Journal:  Am J Ther       Date:  2012-07       Impact factor: 2.688

3.  Gemcitabine-induced radiation recall dermatitis in a patient with resistant Hodgkin lymphoma.

Authors:  Dragomir Marisavljević; Biljana Ristić; Jelena Hajder
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

4.  Gemcitabine associated pseudocellulitis: A missed diagnosis.

Authors:  Dalvir Gill; Josh Schrader; Matthew Kelly; Fidel Martinez; Wajihuddin Syed; Jonathan Wright
Journal:  J Oncol Pharm Pract       Date:  2017-07-16       Impact factor: 1.809

Review 5.  Gemcitabine-Induced Pseudocellulitis in a Patient With Recurrent Lymphedema: A Case Report and Review of the Current Literature.

Authors:  Susanna Curtis; Simon Hong; Rasim Gucalp; Manuela Calvo
Journal:  Am J Ther       Date:  2016 Jan-Feb       Impact factor: 2.688

Review 6.  Gemcitabine-associated "pseudocellulitis" and "pseudosepsis": a case report and review of the literature.

Authors:  Karam M Obeid; Anilrudh A Venugopal
Journal:  Am J Ther       Date:  2013-01       Impact factor: 2.688

Review 7.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

Authors:  W Plunkett; P Huang; Y Z Xu; V Heinemann; R Grunewald; V Gandhi
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

8.  Gemcitabine-induced radiation recall dermatitis: case report.

Authors:  G Bar-Sela; A Beny; R Bergman; A Kuten
Journal:  Tumori       Date:  2001 Nov-Dec

9.  Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma.

Authors:  Eseosa Asemota; Erika Reid; Carrie Kovarik
Journal:  JAAD Case Rep       Date:  2015-06-08

10.  The CARE guidelines: consensus-based clinical case reporting guideline development.

Authors:  Joel J Gagnier; Gunver Kienle; Douglas G Altman; David Moher; Harold Sox; David Riley
Journal:  J Med Case Rep       Date:  2013-09-10
View more
  1 in total

Review 1.  Hyperthermia Treatment as a Promising Anti-Cancer Strategy: Therapeutic Targets, Perspective Mechanisms and Synergistic Combinations in Experimental Approaches.

Authors:  Ga Yeong Yi; Min Ju Kim; Hyo In Kim; Jinbong Park; Seung Ho Baek
Journal:  Antioxidants (Basel)       Date:  2022-03-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.